Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection.

Lambkin-Williams R, Gelder C, Broughton R, Mallett CP, Gilbert AS, Mann A, He D, Oxford JS, Burt D.

PLoS One. 2016 Dec 22;11(12):e0163089. doi: 10.1371/journal.pone.0163089. eCollection 2016.

2.

Low hemagglutinin antigen dose influenza vaccines adjuvanted with AS03 alter the long-term immune responses in BALB/c mice.

Yam KK, Brewer A, Bleau V, Beaulieu É, Mallett CP, Ward BJ.

Hum Vaccin Immunother. 2017 Mar 4;13(3):561-571. doi: 10.1080/21645515.2016.1241360. Epub 2016 Oct 21.

3.

Evaluation of the potential effects of AS03-adjuvanted A(H1N1)pdm09 vaccine administration on the central nervous system of non-primed and A(H1N1)pdm09-primed cotton rats.

Planty C, Mallett CP, Yim K, Blanco JC, Boukhvalova M, March T, van der Most R, Destexhe E.

Hum Vaccin Immunother. 2017 Jan 2;13(1):90-102. doi: 10.1080/21645515.2016.1227518. Epub 2016 Sep 14.

4.

Comparison of AS03 and Alum on immune responses elicited by A/H3N2 split influenza vaccine in young, mature and aged BALB/c mice.

Yam KK, Gupta J, Allen EK, Burt KR, Beaulieu É, Mallett CP, Burt DS, Ward BJ.

Vaccine. 2016 Mar 14;34(12):1444-51. doi: 10.1016/j.vaccine.2016.02.012. Epub 2016 Feb 9.

PMID:
26873056
5.

A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice.

Nachbagauer R, Kinzler D, Choi A, Hirsh A, Beaulieu E, Lecrenier N, Innis BL, Palese P, Mallett CP, Krammer F.

NPJ Vaccines. 2016;1. pii: 16015. doi: 10.1038/npjvaccines.2016.15. Epub 2016 Sep 22.

6.

AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes.

Mallett CP, Beaulieu E, Joly MH, Baras B, Lu X, Liu F, Levine MZ, Katz JM, Innis BL, Giannini SL.

Vaccine. 2015 Jul 31;33(32):3784-7. doi: 10.1016/j.vaccine.2015.06.053. Epub 2015 Jun 19.

7.

Methods to monitor monocytes-mediated amyloid-beta uptake and phagocytosis in the context of adjuvanted immunotherapies.

Hallé M, Tribout-Jover P, Lanteigne AM, Boulais J, St-Jean JR, Jodoin R, Girouard MP, Constantin F, Migneault A, Renaud F, Didierlaurent AM, Mallett CP, Burkhart D, Pilorget A, Palmantier R, Larocque D.

J Immunol Methods. 2015 Sep;424:64-79. doi: 10.1016/j.jim.2015.05.002. Epub 2015 May 19.

8.

AS03-Adjuvanted, Very-Low-Dose Influenza Vaccines Induce Distinctive Immune Responses Compared to Unadjuvanted High-Dose Vaccines in BALB/c Mice.

Yam KK, Gupta J, Winter K, Allen E, Brewer A, Beaulieu É, Mallett CP, Burt DS, Ward BJ.

Front Immunol. 2015 Apr 29;6:207. doi: 10.3389/fimmu.2015.00207. eCollection 2015.

9.

Safety and immunogenicity of a Proteosome -trivalent inactivated influenza vaccine, given nasally to healthy adults.

Langley JM, Halperin SA, McNeil S, Smith B, Jones T, Burt D, Mallett CP, Lowell GH, Fries L.

Vaccine. 2006 Mar 6;24(10):1601-8. Epub 2005 Oct 14.

PMID:
16303215
10.

Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults.

Fries LF, Montemarano AD, Mallett CP, Taylor DN, Hale TL, Lowell GH.

Infect Immun. 2001 Jul;69(7):4545-53.

11.

Epidermal growth factor accelerates recovery of LLC-PK1 cells following oxidant injury.

Andreoli SP, Mallett CP, McAteer JA, Kempson SA, Fineberg N.

In Vitro Cell Dev Biol Anim. 1998 Nov-Dec;34(10):824-30.

PMID:
9870532
12.

Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge.

Glenn GM, Scharton-Kersten T, Vassell R, Mallett CP, Hale TL, Alving CR.

J Immunol. 1998 Oct 1;161(7):3211-4.

13.

Identification of epitope and surface-exposed domains of Shigella flexneri invasion plasmid antigen D (IpaD).

Turbyfill KR, Mertz JA, Mallett CP, Oaks EV.

Infect Immun. 1998 May;66(5):1999-2006.

14.

Disassociation of oxidant-induced ATP depletion and DNA damage from early cytotoxicity in LLC-PK1 cells.

Andreoli SP, Mallett CP.

Am J Physiol. 1997 Jun;272(6 Pt 2):F729-35.

PMID:
9227633
15.
16.
17.

Antibody and cytokine responses in a mouse pulmonary model of Shigella flexneri serotype 2a infection.

van de Verg LL, Mallett CP, Collins HH, Larsen T, Hammack C, Hale TL.

Infect Immun. 1995 May;63(5):1947-54.

18.

Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model.

Mallett CP, VanDeVerg L, Collins HH, Hale TL.

Vaccine. 1993;11(2):190-6.

PMID:
8438617
19.

Patterns of antibody specificity during the BALB/c immune response to hen eggwhite lysozyme.

Newman MA, Mainhart CR, Mallett CP, Lavoie TB, Smith-Gill SJ.

J Immunol. 1992 Nov 15;149(10):3260-72.

PMID:
1431104
20.

Direct quantitative in situ hybridization studies of Ig VH utilization. A comparison between unstimulated B cells from autoimmune and normal mice.

Kastner DL, McIntyre TM, Mallett CP, Hartman AB, Steinberg AD.

J Immunol. 1989 Oct 15;143(8):2761-7.

PMID:
2507638
21.

A substantial proportion of the adult BALB/c available B cell repertoire consists of multireactive B cells.

Rousseau PG, Mallett CP, Smith-Gill SJ.

Mol Immunol. 1989 Oct;26(10):993-1006.

PMID:
2594017
22.

Organ reactive autoantibodies from non-immunized adult BALB/c mice are polyreactive and express non-biased VH gene usage.

Hartman AB, Mallett CP, Srinivasappa J, Prabhakar BS, Notkins AL, Smith-Gill SJ.

Mol Immunol. 1989 Apr;26(4):359-70.

PMID:
2497339
23.

Unusual joining sites in the H and L chains of an anti-lysozyme antibody.

Hartman AB, Mallett CP, Sheriff S, Smith-Gill SJ.

J Immunol. 1988 Aug 1;141(3):932-6.

PMID:
3135317
24.

VH family usage and binding analyses of polyreactive monoclonal autoantibodies derived from nonimmunized adult BALB/c mice.

Hartman AB, Mallett CP, Srinivasappa J, Prabhakar BS, Notkins AL, Smith-Gill SJ.

Curr Top Microbiol Immunol. 1988;137:211-5. No abstract available.

PMID:
3138074
25.

Role of glutathione in protecting endothelial cells against hydrogen peroxide oxidant injury.

Andreoli SP, Mallett CP, Bergstein JM.

J Lab Clin Med. 1986 Sep;108(3):190-8.

PMID:
3091744
26.

Dental caries vaccine: some problems solved?

Everhart DL, Mallett CP, Doyle G.

Microbiol Sci. 1985 Oct;2(10):312-3. Review.

PMID:
3939986
27.

Competent antigen-binding fragments (Fab) from secretory immunoglobulin A using Streptococcus sanguis immunoglobulin A protease.

Mallett CP, Boylan RJ, Everhart DL.

Caries Res. 1984;18(3):201-8. No abstract available.

PMID:
6423284

Supplemental Content

Loading ...
Support Center